1. Home
  2. PRTA vs KRNY Comparison

PRTA vs KRNY Comparison

Compare PRTA & KRNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$10.62

Market Cap

539.9M

Sector

Health Care

ML Signal

HOLD

Logo Kearny Financial Corp

KRNY

Kearny Financial Corp

HOLD

Current Price

$7.98

Market Cap

504.9M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRTA
KRNY
Founded
2012
1884
Country
Ireland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Savings Institutions
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
539.9M
504.9M
IPO Year
2013
2014

Fundamental Metrics

Financial Performance
Metric
PRTA
KRNY
Price
$10.62
$7.98
Analyst Decision
Buy
Buy
Analyst Count
9
2
Target Price
$19.00
$8.00
AVG Volume (30 Days)
462.3K
286.4K
Earning Date
05-07-2026
04-23-2026
Dividend Yield
N/A
5.47%
EPS Growth
N/A
130.22
EPS
N/A
0.30
Revenue
$814,000.00
$2,580,000.00
Revenue This Year
$1,111.38
$3.89
Revenue Next Year
N/A
$17.52
P/E Ratio
N/A
$26.80
Revenue Growth
N/A
36.00
52 Week Low
$4.32
$5.76
52 Week High
$11.69
$8.50

Technical Indicators

Market Signals
Indicator
PRTA
KRNY
Relative Strength Index (RSI) 64.85 61.88
Support Level $9.69 $7.77
Resistance Level $10.90 $8.42
Average True Range (ATR) 0.41 0.16
MACD 0.11 0.08
Stochastic Oscillator 95.21 76.47

Price Performance

Historical Comparison
PRTA
KRNY

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

About KRNY Kearny Financial Corp

Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income.

Share on Social Networks: